Literature DB >> 15714480

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.

Evangelista Sagnelli1, Tommaso Stroffolini, Alfonso Mele, Piero Almasio, Nicola Coppola, Luigina Ferrigno, Carlo Scolastico, Mirella Onofrio, Michele Imparato, Pietro Filippini.   

Abstract

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor in 56.3% of all the patients. Hepatitis B surface antigen (HBsAg) was present in the serum of 13.4% of the cases (in 10% it was the only etiological factor). A history of alcohol abuse was found in 23% of the cases (9.4% without viral infection). The prevalence of HCV-related cases was significantly lower in incident than in prevalent cases (44.9% vs. 59.9%, P < 0.0001), while the proportion of patients with alcohol abuse was much higher in incident than in prevalent cases (18.1% vs. 6.6%, P < 0.0001). These findings indicate that nearly one quarter of patients with chronic liver diseases in Italy have a severe disease such as liver cirrhosis and HCC represents a not negligible burden for the national health system. Hepatitis B fell in importance as an etiological factor. Hepatitis C is the important pathogenic factor for chronic liver disease in Italy. However, a comparison between the prevalent and incident cases suggests that in future HCV infection will also play a progressively decreasing role, in part as a consequence of treatment. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15714480     DOI: 10.1002/jmv.20313

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  21 in total

1.  Bacterial meningitis complicating the course of liver cirrhosis.

Authors:  Pasquale Pagliano; Giovanni Boccia; Francesco De Caro; Silvano Esposito
Journal:  Infection       Date:  2017-06-14       Impact factor: 3.553

Review 2.  Hepatitis B virus and hepatitis C virus infection in healthcare workers.

Authors:  Nicola Coppola; Stefania De Pascalis; Lorenzo Onorato; Federica Calò; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2016-02-18

3.  Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy.

Authors:  Evangelista Sagnelli; Tommaso Stroffolini; Caterina Sagnelli; Mario Pirisi; Sergio Babudieri; Guido Colloredo; Maurizio Russello; Nicola Coppola; Giovanni Battista Gaeta; Bruno Cacopardo; Massimo De Luca; Piero Luigi Almasio
Journal:  Infection       Date:  2017-11-17       Impact factor: 3.553

4.  Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care.

Authors:  Irene Cacciola; Riccardo Scoglio; Angela Alibrandi; Giovanni Squadrito; Giovanni Raimondo
Journal:  Intern Emerg Med       Date:  2016-09-19       Impact factor: 3.397

5.  Impact of comorbidities on the severity of chronic hepatitis B at presentation.

Authors:  Evangelista Sagnelli; Tommaso Stroffolini; Alfonso Mele; Michele Imparato; Caterina Sagnelli; Nicola Coppola; Piero Luigi Almasio
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

Review 6.  Hepatitis B virus infection in immigrant populations.

Authors:  Nicola Coppola; Loredana Alessio; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Rosa Zampino; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2015-12-28

Review 7.  Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.

Authors:  H Zhou; H Luo; S Xiao; H Wang; G Gong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-06       Impact factor: 3.267

Review 8.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 9.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

10.  Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.

Authors:  Paola Mancino; Katia Falasca; Claudio Ucciferri; Eligio Pizzigallo; Jacopo Vecchiet
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-03-31       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.